What we claim is:

Claim 1. Use of a composition in the manufacture of a medicament for treating a cancer expressing CD19 in a subject,

wherein the composition includes therapeutic T cells specifically targeting CD19 and cells expressing CD19;

wherein the therapeutic T cells are T cells (CAR-T cells) including a chimeric antigen receptor (CAR), and the cells expressing CD19 are living T cells that have not been irradiated;

wherein the treatment includes:

(a) administering to the subject CAR-T cells specifically targeting CD19 at a therapeutically effective amount of 10^4 to 10^9 cells/kg body weight;

(b) after step (a), administering the cells expressing CD19 to the subject at a stimulatory effective amount of 10^3 to10^6 cells/kg body weight.

Claim 2. Use according to claim 1, wherein the CAR-T cells are administered once or more times.

Claim 3. Use according to claim 1, wherein the cells expressing CD19 are administered once or more times.

Claim 4. Use according to claim 3, wherein the cells expressing CD19 are administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, or 20 days after the CAR-T cells are administered.

Claim 5. Use according to any one of claims 1 to 4, wherein the cells expressing CD19 are administered after the cancer cell load is reduced by administering the CAR-T cells; or after the CAR-T cells are administered, when the amount of the CAR-T cells in the subject decreases, the cells expressing CD19 are administered.

Claim 6. Use according to claim 5, wherein after the cancer cell load is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, the cells expressing the CD19 are administered.

Claim 7. The use according to any one of claims 1 to 6, wherein after the cancer is completely remitted by administering the CAR-T cells, the cells expressing CD19 are administered.

Claim 8. Use according to claim 1, wherein the CAR comprises an extracellular antigen binding domain against CD19.

Claim 9. Use according to claim 1, wherein the CD19 is expressed on the surface of the living T cells.

Claim 10. Use according to 1 to 9, wherein the cells expressing CD19 are derived from immune cells.

Claim 11. Use according to any one of claims 1 to 10, wherein the CAR-T cells and/or the cells expressing CD19 are derived from autologous cells of the subject.

Claim 12. Use according to any one of claims 1 to 10, wherein the CAR-T cells and/or the cells expressing the CD19 are derived from allogeneic cells.

Claim 13. Use of a composition in the manufacture of a medicament for preventing progression or recurrence of cancer expressing CD19 in a subject,

wherein the composition includes therapeutic T cells specifically targeting CD19 and cells expressing CD19;

wherein the therapeutic T cells are T cells (CAR-T cells) including a chimeric antigen receptor (CAR), and the cells expressing CD19 are living T cells that have not been irradiated;

wherein the preventing includes:

(a) administering to the subject CAR-T cells specifically targeting CD19 at a therapeutically effective amount of 10^4 to 10^9 cells/kg body weight;

(b) after step (a), administering the cells expressing CD19 to the subject at a stimulatory effective amount of 10^3 to10^6 cells/kg body weight.

Claim 14. Use according to claim 13, wherein the cells expressing CD19 are administered one or more times.

Claim 15. Use according to claim 13 or 14,, wherein the cells expressing CD19 are administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, or 20 days after the CAR-T cells are administered.

Claim 16. Use according to any one of claims 13 to 15, wherein the cells expressing CD19 are administered after the cancer cell load is reduced by administering the CAR-T cells.

Claim 17. Use according to claim 16, wherein after the cancer cell load is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, the cells expressing CD19 are administered.

Claim 18. Use according to any one of claims 13 to 17, wherein after the cancer is completely remitted by administering the CAR-T cells, the cells expressing CD19 are administered.

Claim 19. Use according to claim 13 or 18, wherein the CAR comprises an extracellular antigen binding domain against CD19.

Claim 20. Use according to claim 13, wherein the CD19 is expressed on the surface of the living T cells.

Claim 21. The use according to any one of claims 13 to 20, wherein the cells expressing CD19 are derived from immune cells.

Claim 22. Use according to any one of claims 13 to 21, wherein the CAR-T cells and/or the cells expressing CD19 are derived from autologous cells of the subject.

Claim 23. Use according to any one of claims 13 to 20, wherein the CAR-T cells and/or the cells expressing CD19 are derived from allogeneic cells.

Claim 24. A combination for treating cancer expressing CD19 in a subject, or preventing progression or recurrence of cancer expressing CD19 in a subject,
wherein the combination includes therapeutic T cells specifically targeting CD19 and cells expressing CD19;
wherein the therapeutic T cells are T cells (CAR-T cells) including a chimeric antigen receptor (CAR), and the cells expressing CD19 are living T cells that have not been irradiated;
wherein the CAR-T cells contain CAR-T cells at a therapeutically effective amount of 10^4 to 10^9 cells/kg body weight, and the cells expressing CD19 contain the cells expressing CD19 at a stimulatory effective amount of 10^3 to10^6 cells/kg body weight.

Claim 25. A kit comprising the combination according to claim 24, wherein the kit is used for treating cancer expressing CD19 in a subject or preventing progression or recurrence of cancer expressing CD19 in a subject.